COVID-19 vaccination and immune thrombocytopenia

Article Hematology

Misdiagnosed thrombocytopenia in children and adolescents: analysis of the Pediatric and Adult Registry on Chronic ITP

Alexandra Schifferli et al.

Summary: Diagnosis of secondary ITP or non-IT in children requires consideration of individual case details and underlying causes, with younger ages typically associated with infectious or autoimmune diseases, while malignancies and aplastic anemia should be considered in older patients.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Hematology

Prothrombotic immune thrombocytopenia after COVID-19 vaccination

Andreas Tiede et al.

Summary: This study reports 5 cases of prothrombotic immune thrombocytopenia following vaccination with AZD1222. Patients presented with various clinical manifestations, including thrombocytopenia and elevated D-dimer levels. Treatment experience suggests that anticoagulation may be effective, but there is also a risk of unusual and severe thromboembolic events.

BLOOD (2021)

添加到收藏夹

Article Medicine, General & Internal

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

Eleftheria Vasileiou et al.

Summary: The study in Scotland found that the first doses of the BNT162b2 mRNA and ChAdOx1 vaccines were associated with substantial reductions in the risk of COVID-19 hospital admission, with vaccine effectiveness ranging from 88% to 91% at 28-34 days post-vaccination.

LANCET (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia

Douglas B. Cines et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

C. R. Simpson et al.

Summary: Analysis of data from the EAVE II cohort in Scotland has shown that a first dose of the ChAdOx1 nCoV-19 vaccine may be associated with increased risks of idiopathic thrombocytopenic purpura, arterial thromboembolic events, and hemorrhagic events. However, there were no positive associations found between the BNT162b2 vaccine and these adverse events.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal